Aiming to forge deeper into the cancer market, Amgen Inc. is taking from its well-stocked coffers to buy 21.3 percent of Tularik Inc. - $35 million worth of newly issued stock at $10 per share - as part of a deal that includes an oncology collaboration and a total of $125 million in committed funding. (BioWorld Today) Read More
